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stimulated a proliferative response in ECs. These studies 
highlight the potential that small molecules that stimulate 
or block GPR35 activity can modulate vascular proliferation 
and migration. These data propose GPR35 as a translational 
therapeutic target in vascular remodeling. 
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 Introduction 
 The use of autologous human saphenous vein (HSV) is 
the most common surgical intervention for the bypass of 
occluded multivessel coronary artery disease (CAD), de-
spite the use of alternative sources of graft such as the in-
ternal mammary artery. Although successful in reducing 
overall rates of mortality and morbidity in CAD patients, 
50% of long-term vein grafts become occluded due to inti-
mal hyperplasia  [1] . The pathophysiology of vein graft dis-
ease is defined by a cascade of events leading to neointimal 
formation and graft occlusion. Migration and proliferation 
of smooth muscle cells (SMCs) is central to neointimal de-
velopment, which, if unchecked, leads to occlusion of the 
graft via superimposed atheroma. Current therapeutic op-
tions are limited to repeat intervention to replace the oc-
cluded grafts. Vascular remodeling is, therefore, an impor-
tant target for the development of new therapies.
 Key Words 
 G-protein-coupled receptor · Vascular smooth muscle 
cells · Rho kinase 
 Abstract 
 Vascular smooth muscle cell (VSMC) migration and prolifera-
tion is central to neointima formation in vein graft failure fol-
lowing coronary artery bypass. However, there are currently 
no pharmacological interventions that prevent vein graft 
failure through intimal occlusion. It is hence a therapeutic 
target. Here, we investigated the contribution of GPR35 to 
human VSMC and endothelial cell (EC) migration, using a 
scratch-wound assay, and also the contribution to prolifera-
tion, using MTS and BrdU assays, in in vitro models using re-
cently characterized human GPR35 ortholog-selective small-
molecule agonists and antagonists. Real-time PCR studies 
showed GPR35 to be robustly expressed in human VSMCs 
and ECs. Stimulation of GPR35, with either the human-selec-
tive agonist pamoic acid or the reference agonist zaprinast, 
promoted VSMC migration in the scratch-wound assay. 
These effects were blocked by coincubation with either of 
the human GPR35-specific antagonists, CID-2745687 or ML-
145. These GPR35-mediated effects were produced by in-
ducing alterations in the actin cytoskeleton via the Rho A/
Rho kinase signaling axis. Additionally, the agonist ligands 
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 G-protein-coupled receptors (GPCRs) remain the 
best-studied class of cell surface receptors and the most 
tractable family of proteins for the discovery of novel, 
small-molecule drugs  [2, 3] . However, even in examples 
in which tissue distribution and genetic ablation data sug-
gest important roles in pathophysiology, a considerable 
number of GPCRs remain poorly characterized, and, in 
a significant number of these cases, the endogenous 
ligand(s) that activate them remain undefined or of ques-
tionable physiological relevance  [4, 5] . GPR35 is an ex-
ample of this. Despite initially being discovered over a 
decade ago as an intronless, open-reading frame on chro-
mosome 2 corresponding to 309 amino acids  [6] and kyn-
urenic acid (KNU) being identified as an endogenously 
generated agonist of the receptor  [7] , GPR35 remains de-
fined as an orphan, due to questions of the effectiveness 
of this ligand at the human receptor ortholog  [8] . Evi-
dence suggests that plasma KNU is only in the nanomolar 
range physiologically  [9, 10] , although it has been pro-
posed that levels may reach the micromolar range in in-
flammation and this may therefore activate GPR35  [7] . 
However, to date, the consensus would suggest that KNU 
levels are likely to be insufficient for it to be the true en-
dogenous ligand for GPR35  [11] . Pharmacological char-
acterization of GPR35 has been particularly challenging, 
both because the nature of the endogenous ligand(s) re-
mains uncertain and because many identified synthetic 
ligands display substantial selectivity between species or-
thologs  [8, 12] . This has greatly restricted the capacity to 
interrogate the contribution of GPR35 in rodent models 
of disease, including vascular disease. Furthermore, 
GPR35 displays a limited capacity to signal via the com-
monly studied G-protein-mediated pathways. We have 
previously reported that GPR35 interacts selectively with 
Gα 13  [13, 14] , a G protein often considered to regulate the 
Rho A/Rho kinase cascade and hence to promote altera-
tions of the cytoskeleton that result in cellular shape 
change and altered cellular migration  [15–17] . Other 
study groups have also suggested that GPR35 can couple 
to the G i /G o group of inhibitory G proteins, leading to 
ERK1/2 activation, at least in certain cell types  [18–20] . 
Moreover, although the identification of novel synthetic 
agonists of GPR35 has often relied on the ability of ago-
nist-occupied GPR35 to recruit β-arrestin-2  [18, 21] , the 
functional outputs and consequences of this interaction 
remain unclear in terms of cellular regulation. 
 As well as a number of synthetic agonists  [22, 23] , an-
tagonists from 2 distinct chemical classes have recently 
been identified. The prototypic exemplars of these are 
CID-2745687 and ML-145  [24, 25] . However, although 
not appreciated immediately  [18] , both of these ligands 
have been shown to be highly selective for the human or-
tholog of GPR35  [14] and show no significant affinity at 
rodent orthologs. Thus, although not suitable to help de-
fine the role of GPR35 in rodent models, they do poten-
tially provide key pharmacological tools to explore the 
contribution of GPR35 in human cells and tissues.
 Expression of GPR35 is high in the small intestine and 
also in specific immune cells such as peripheral leuko-
cytes, monocytes and neutrophils  [7] . However, there are 
also reports of expression in other tissues and cell types 
including in the kidney and heart and in regions of the 
nervous system linked to pain perception  [12] . Further-
more, a second isoform of human (h)GPR35 with an N-
terminal extension has been identified, although it dis-
plays highly similar pharmacology as the short isoform 
 [18, 26] . Although not widely investigated in the cardio-
vascular system to date, GPR35 has previously been im-
plicated in cardiovascular disease. First, a nonsynony-
mous, single-nucleotide polymorphism has been report-
ed to have a significant association with CAD in a 
sibship-based case control cohort  [27] . Second, in a mi-
croarray screen of heart failure patients, GPR35 was re-
ported to have increased expression levels in failing myo-
cardium and in vitro overexpression of GPR35 in cardio-
myocytes induced hypertrophy and decreased cell 
viability  [28] . Moreover, GPR35 knockout mice are re-
ported to have significantly increased blood pressure 
compared to their wild-type littermates  [28] . Most re-
cently, GPR35 expression was reported to be induced by 
hypoxia-inducible factor-1 in hypoxic cardiomyocytes, 
leading to changes in the actin cytoskeleton  [29] . 
 Here, we have used the developing knowledge of 
GPR35 pharmacology to explore a role for GPR35 in hu-
man primary vascular endothelial cells (ECs) and SMCs. 
We demonstrate that activation of GPR35 can contribute 
to the increased migration and proliferation of primary 
HSV vascular cells and that antagonism of its activity 
blocks these effects. These data suggest that GPR35 an-
tagonism may be an important, novel and translational 
therapeutic target.
 Materials and Methods 
 Materials for the cell culture were from Sigma-Aldrich (Gil-
lingham, Dorset, UK), Life Technologies (Paisley, Strathclyde, 
UK) or PAA Laboratories Ltd. (Yeovil, Somerset, UK). Polyethyl-
enimine (PEI) linear MW-25000 was from Polysciences Inc. (War-
rington, Pa., USA). CID-2745687, ML-145 and  zaprinast were pur-
chased from Tocris Bioscience (Bristol, UK). 
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 Bioluminescence Resonance Energy Transfer 
 HEK293T cells were maintained in Dulbecco’s modified Ea-
gle’s medium (DMEM) supplemented with 0.292 g/l  L -glutamine 
and 10% (v/v) newborn-calf serum at 37   °   C in a 5% CO 2 humidi-
fied atmosphere. Cells were transfected with FLAG-tagged 
hGPR35 enhanced yellow fluorescent protein (FLAG-hGPR35-
eYFP) and β-arrestin-2- Renilla  luciferase 6 (ratio 4: 1), using 1 mg/
ml PEI. After 24 h, cells were washed with Hanks’ balanced salt 
solution (pH 7.4), and coelentrazine-h (Promega) was added to a 
final concentration of 5 μ M . Cells were incubated in darkness for 
10 min at 37  °  C before the addition of receptor ligands. Cells were 
incubated for a further 5 min at 37  °  C before BRET measurements 
were performed using a PHERAstar FS reader (BMG-Labtech, Of-
fenburg, Germany). The BRET ratio was calculated as a wave-
length emission at 530/485 nm and expressed as the percentage of 
maximal signal for each ligand  [13, 14] .
 Inositol Phosphate Generation Assays 
 Inositol phosphate (IP) accumulation was measured using a ho-
mogenous time-resolved FRET (HTRF) assay (HTRF IP-One Tb kit, 
Cisbio Bioassays, Codolet, France). HEK293T cells were transiently 
cotransfected with FLAG-hGPR35-eYFP and the G-protein chimae-
ra Gα q/13 5 (a form of Gα q in which the C-terminal 5 amino acids were 
replaced with the corresponding pentapeptide from Gα 13 ) using PEI. 
After 16–24 h of incubation at 37  °  C in a 5% CO 2 humidified atmo-
sphere, the cells were resuspended in IP-One stimulation buffer (10 
m M HEPES, 1 m M CaCl 2 , 0.5 m M MgCl 2 , 4.2 m M KCl, 146 m M NaCl, 
5.5 m M glucose and 50 m M LiCl, pH7.4) and seeded at 10,000 cells/
well in white, solid-bottom, 384-well plates. Ligands were diluted in 
IP-One stimulation buffer according to the manufacturer’s instruc-
tions. Antagonist compounds were preincubated with cells for 15 
min at 37   °   C prior to the addition of the agonist. Cells were incu-
bated with ligand(s) for 2 h at 37   °   C, before the addition of d 2 -con-
jugated IP monophosphate (IP 1 ; 3 μl/well) and anti-IP 1 Lumi4 TM -Tb 
cryptate (3 μl/well) diluted in lysis buffer. After incubation at room 
temperature for 1 h, HTRF was measured using a PHERAstar FS 
plate reader (BMG-Labtech). IP 1 accumulation was measured by the 
fluorescence ratio of 665 nm/620 nm. 
 Quantifying GPR35 Expression 
 In order to quantify GPR35 expression levels in individual or-
gans, a commercial cDNA panel (Life Technologies) prepared 
from normal human tissue was utilized. For vascular cells, RNA 
was extracted from cells plated in 6-well plates using an RNeasy 
RNA extraction kit as per the manufacturer’s instructions (Qiagen, 
Crawley, UK). Reverse-transcriptase reactions were carried out 
 using a Taqman Multiscribe RT kit with random hexamers ac-
cording to the manufacturer’s instructions. mRNA expression of 
hGPR35 and ribosomal 18S were quantified by real-time PCR us-
ing Taqman chemistries (Applied Biosystems, Warrington, UK). 
The mRNA expression level of GPR35 in tissues was expressed as 
a relative quantification (RQ) or ΔCT value normalized to the 
housekeeper gene ribosomal 18S, and was further normalized to 
levels in the heart. For quantification of expression in cells, the 
GPR35 copy number per nanogram of total RNA was calculated 
by constructing a standard curve for FLAG-hGPR35-eYFP in 
 pcDNA3 (7046 bp)  [21] . The mass per copy was calculated using 
the formula m = (n)(1/Avogadro’s number)(average molecular 
weight of 1 bp), where n = plasmid bp. Serial dilutions of 30–
300,000 copies were added per TaqMan reaction.
 Isolation and Culture of Primary Human Vascular ECs and 
SMCs 
 Vascular cells were grown from medial explants from HSV seg-
ments obtained from male and female patients undergoing coro-
nary artery bypass grafting and who gave their informed consent. 
Ethical permission was obtained from the West of Scotland Re-
search Ethics Committee 4 (reference No. 10/S0704/60) and the 
investigation conformed to the principles outlined in the Declara-
tion of Helsinki. HSV SMCs were maintained in DMEM with 
4,500 mg/l glucose supplemented with 15% (v/v) fetal-calf serum 
(FCS) and 100 IU/ml penicillin, 100 IU/ml streptomycin and 
2 mmol/l  L -glutamine. HSV ECs were maintained in EC complete 
medium (TCS Cellworks, UK) and supplemented with 20% FCS 
(PAA Laboratories, Yeovil, UK). 
 Cellular Morphology Assays 
 HSV SMCs or ECs were seeded in 6-well plates at 1 × 10 5 cells/
well and quiesced for 48 or 24 h, respectively. Following 45 min of 
exposure to GPR35 ligands at 37   °  C, the cells were fixed using 4% 
paraformaldehyde, and stained with TRITC F-actin phalloidin at 
5 μg/ml for 1 h at room temperature (Sigma). Cells were washed 
and mounted with Prolong ® Gold Antifade reagent with DAPI 
(Invitrogen) and were then imaged using a spinning disk-struc-
tured illumination Viva Tome device and analyzed using ImageJ 
software. Equivalent studies were performed on the Flp-In TM T-
REx TM  293 cell line harboring FLAG-hGPR35-eYFP at the Flp-In 
T-REx locus  [14, 21] . In such cells, expression of the protein lo-
cated at the Flp-In T-REx locus is achieved only upon addition of 
doxycycline or tetracycline. In the absence of treatment with dox-
ycycline or tetracycline, such cells act as a negative control.
 Scratch-Wound Healing Migration Assay 
 Cells were seeded in 6-well plates at 3 × 10 5 cells/well, grown to 
confluence and then quiesced for 48 or 24 h for VSMC and EC, 
respectively. Three horizontal scratches per well were created be-
fore stimulation with various concentrations of pamoic acid (Sig-
ma-Aldrich) or zaprinast in serum-free DMEM. In a number of 
experiments, a GPR35 agonist was coadded with 100 n M of either 
of the human-specific GPR35 antagonists, CID-2745687 and ML-
145. In equivalent studies, the structurally and mechanistically dis-
tinct Rho A pathway inhibitors, Y-27632  [30–32] or Y-16  [33] , 
were coadministered with a GPR35 agonist. Images of the cells 
were acquired at time zero, followed by incubation at 37   °   C. The 
cells were imaged up to a maximum period of 36 h. Percentage 
migration was assessed by measuring the distance (μm) between 
cells migrating into the wound area in 10 random fields of view per 
scratch over the time course using ImageJ software.
 Cell Proliferation 
 HSV SMCs and ECs were seeded in clear, 96-well plates at a den-
sity of 5 × 10 3 cells/well and quiesced in full medium, without serum 
for 48 or 24 h, respectively. The cells were then stimulated with a 
range of concentrations of ligands ±5% FCS, over a period of 48 h 
(SMCs) or 24 h (ECs). Cell proliferation was assessed using either 
Cell Titer 96 aqueous nonradioactive cell proliferation assay (MTS; 
Promega, Madison, Wis., USA) or the 5-bromo-2′-deoxyuridine 
(BrdU) cell proliferation assay kit (Cell Signaling Technology, UK) 
according to manufacturer’s instructions. Colorimetric output was 
measured on a Wallac VICTOR 2 plate reader at absorbance values 
of 490 or 450 nm for the MTS and BrdU assays, respectively.
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 Statistical Analysis 
 All data are provided as mean ± SEM and were analyzed using 
GraphPad Prism ® software. Student’s t test for paired data and 
one-way ANOVA with Dunnett’s test for multiple comparisons 
were applied and a statistical difference was considered if p < 0.05. 
Taqman, β-arrestin-2 and IP 1 accumulation experiments were 
performed in duplicate. All other experiments were performed in 
triplicate on each occasion. N values for each experiment in the 
figure legends indicate the number of times an experiment was re-
peated. Individual cell numbers/numbers of measurements made 
for migration and cell size experiments are indicated separately.
 Results 
 Pharmacological Assessment of GPR35 Ligands at 
hGPR35 
 Zaprinast and pamoic acid have both been reported to 
be agonist ligands of hGPR35  [21] . This was confirmed 
initially by measuring β-arrestin-2 recruitment to the re-
ceptor using BRET studies. These were performed in 
HEK293T cells transfected to transiently coexpress a 
form of hGPR35 C-terminally tagged with eYFP and 
β-arrestin-2 tagged with  Renilla luciferase ( fig.  1 a). As 
shown previously  [21] , pamoic acid  (pEC 50 = 7.30 ± 0.06) 
was more potent than zaprinast (pEC 50 = 5.44 ± 0.01; 
means ± SEM, n = 6). Both these ligands were also able to 
promote the production of IPs when hGPR35 was tran-
siently coexpressed with the chimeric G protein Gα q/13 5 
 [34] . In this assay, which reflects the capacity of the recep-
tor to interact with the Rho A-linked G protein Gα 13  [17, 
34] , both zaprinast (pEC 50 = 6.83 ± 0.06) and pamoic acid 
(pEC 50 = 8.36 ± 0.11; means ± SEM; n = 5 in each case) 
were more potent than recorded in the β-arrestin-2 re-
cruitment assay ( fig. 1 b). This reflects that there is fre-
quently receptor reserve in G-protein-mediated signal 
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 Fig. 1. The GPR35 antagonists CID-2745687 and ML-145 blocked 
agonist-induced hGPR35 activation in 2 distinct assays. Activation 
of hGPR35 by varying concentrations of the agonists pamoic acid 
and zaprinast in a β-arrestin-2 interaction assay ( a ), where FLAG-
hGPR35-eYFP was cotransfected with β-arrestin-2- Renilla  lucifer-
ase in HEK293T cells (n = 6), or an IP 1 accumulation assay ( b ), 
where FLAG-hGPR35-eYFP was cotransfected with Gα q/13 5 in 
HEK293T cells (n = 5). hGPR35 activation following cotransfec-
tion of FLAG-hGPR35-eYFP and Gα q/13 5 in HEK293T cells mea-
sured via an IP 1 accumulation assay was inhibited in a concentra-
tion-dependent manner following exposure to increasing concen-
trations of ML-145 and CID-2745687 in the presence of either 
zaprinast ( c ; n = 5) or  pamoic acid ( d ; n = 7) at EC 80 concentrations 
of the agonist ligand. Data are shown as means ± SEM. 
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transduction events that is not routinely evident in the 
β-arrestin-2 recruitment assay. Using this IP accumula-
tion assay as a surrogate measure of interactions of the 
receptor with Gα 13 , both ML-145 and CID-2745687 were 
able to fully block the agonist effect of either zaprinast 
( fig. 1 c) or pamoic acid ( fig. 1 d) at hGPR35, confirming 
their suitability to act as highly selective inhibitors of 
GPR35 in cells and tissues of human origin. Once again, 
as described previously  [14] , ML-145 displayed some 50-
fold higher affinity than CID-2745687 as an hGPR35 an-
tagonist ( fig. 1 c, d). As noted previously, GPR35 displays 
a level of constitutive activity in G-protein-mediated as-
says, and both CID-2745687 and ML-145 acted as inverse 
agonists  [14] , able to suppress constitutive activity as well 
as the agonist effects of pamoic acid and zaprinast in the 
IP 1 accumulation assay ( fig. 1 c, d).
 Expression of GPR35 in Human Vascular Cells and 
Tissue 
 Next, expression of GPR35 was investigated at the 
mRNA level using a human tissue cDNA panel ( fig. 2 a). 
Consistent with previous reports  [7, 35] , high levels of 
hGPR35 were detected in the small intestine, colon and 
spleen. It was also noted that hGPR35 mRNA expression 
could be detected in many other tissues of the body in-
cluding the kidney and cervix, albeit at lower levels 
( fig. 2 a). Interestingly, expression was also high in HSV 
ECs ( fig. 2 a). To explore the vascular expression of GPR35 
more extensively, RNA from HSV ECs, HSV SMCs and 
human umbilical-vein ECs (HUVECs) was reverse-tran-
scribed and examined via real-time qRT-PCR and copy 
number in each cell type calculated ( fig. 2 b). Substantial 
levels of GPR35 expression were detected in all 3 vascular 
cell types with copy numbers of 3.99 ± 0.61 copies/ng to-
tal RNA in HUVECs, 28.5 ± 2.2 copies/ng total RNA in 
HSV ECs and 10.2 ± 0.76 copies/ng total RNA in HSV 
SMCs, although they were significantly lower than the 
levels detected in the colon carcinoma cell line, HT-29 
(871.0 ± 63.47 copies/ng total RNA;  fig. 2 b). Interestingly, 
previous studies have suggested levels of expression of 
GPR35 in HUVECs to be barely detectable  [36] .
 Effects of GPR35 Stimulation on the HSV SMC 
Cytoskeleton 
 To date, there have been no direct studies investigating 
the functional outcomes of GPR35 activation in human 
vascular cells, although the capacity of intercellular adhe-
sion molecule (ICAM)-1 expressing HUVECs to interact 
with leukocytes in a GPR35-dependent manner has been 
reported  [36] . Since stimulation of GPR35 is known to 
result in the activation of G α13 ( fig. 1 b)  [13] , and this is 
frequently associated with downstream signaling via Rho 
A  [17] , the effects of GPR35 ligand exposure on HSV 
SMC cytoskeleton arrangement and migration were ex-
amined ( fig. 3 ). Prior to this, the effect of GPR35 activa-
tion in Flp-In T-REx  293 cells harboring FLAG-hGPR35-
eYFP at the Flp-In T-REx  locus  [21] was analyzed. In the 
absence of doxycycline induction, FLAG-hGPR35-eYFP 
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500 n M pamoic acid (PAM) 24 h later, ei-
ther alone or in the presence of 100 n M 
CID-2745687 (CID) or 100 n M ML-145 for 
45 min (n = 4 per condition). Cells were 
stained for F-actin using TRITC actin phal-
loidin and imaged via spinning-disk illu-
mination VivaTome TM microscopy. Scale 
bar = 20 μm.  b Representative images of 
quiescent HSV SMCs fixed and stained for 
F-actin following stimulation with 100 n M 
of PAM ± antagonists CID or ML-145 for 
45 min (n = 3). Scale bars = 50 μm. Arrows 
highlight changes in actin filament organi-
zation following pamoic acid stimulation. 
 c Quantification of HSV SMC length (μm) 
in the presence of 100 n M PAM ± antago-
nists CID and ML-145 (3 experiments; 40–
60 cells measured/condition/experiment). 
Data are shown as means ± SEM.  *   p < 
0.001 versus serum control, analyzed via 
1-way ANOVA with Dunnett’s test for 
multiple comparisons. 
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is not expressed by these cells, providing a negative con-
trol for possible nonreceptor-mediated effects of the li-
gands. Here, exposure to pamoic acid (500 n M ) did not 
induce any changes in cell morphology ( fig. 3 a). More-
over, in the absence of ligand addition, induction of ex-
pression of FLAG hGPR35-eYFP also did not produce 
alteration in cell morphology. However, in cells treated 
with doxycycline to induce FLAG-hGPR35-eYFP expres-
sion, exposure to pamoic acid for 45 min did now pro-
duce alterations in cell morphology, with cells becoming 
contracted in appearance and alteration of the actin cyto-
skeleton, from its resting disorganized arrangement, to 
defined structures localized at the plasma membrane 
( fig.  3 a). These effects were blocked when pamoic acid 
was coincubated along with either of the GPR35 antago-
nists CID-2745687 or ML-145 ( fig. 3 a), confirming that 
these alterations in cellular morphology reflected the ac-
tivation of GPR35. Next, the effects of the ligands on HSV 
SMC morphology and cytoskeletal rearrangement were 
examined ( fig. 3 b, c). Incubation with the hGPR35-selec-
tive agonist pamoic acid resulted in changes in the HSV 
SMCs, in which the resting unorganized actin cytoskele-
ton rearranged into aligned stress fibers at the plasma 
membrane, with cells becoming elongated in appearance 
in comparison to agonist-free conditions ( fig. 3 b). These 
effects were lacking when cells were coincubated with 
pamoic acid and either CID-2745687 or ML-145 ( fig. 3 b). 
Quantification of cell length using ImageJ revealed that 
addition of the hGPR35 agonist pamoic acid induced a 
significant increase in length of the HSV SMCs from 
366.2 ± 12.5 to 440.6 ± 15.7 μm (p < 0.001;  fig. 3 c). This 
effect was completely abolished following coincubation 
of pamoic acid with either CID-2745687 or ML-145, sug-
gesting that in primary human vascular cells, the specific 
activation of GPR35 was able to induce changes in cell 
architecture, leading to changes in cell size ( fig. 3 c).
 Effects of GPR35 Stimulation on HSV SMC Migration 
and Proliferation 
 The role of GPR35 in the migration of HSV SMCs was 
assessed using the GPR35 agonists zaprinast and pamoic 
acid in a scratch-wound healing assay. Both GPR35 ago-
nists significantly enhanced HSV SMC migration with 
500 n M zaprinast inducing migration by 28.2 ± 1.8% and 
100 n M pamoic acid by 23.9 ± 3.3% higher than that ob-
served in comparison to serum-free control-quiesced 
HSV SMCs (p < 0.001;  fig. 4 a–c). Moreover, at the most 
effective concentrations, the GPR35 agonists promoted 
migration as successfully as FCS (30.1 ± 2.3%). Next, the 
effects of coincubating cells with 100 n M pamoic acid and 
100 n M of either of the hGPR35 antagonists, CID-2745687 
and ML-145, was studied. Both antagonists completely 
blocked pamoic-acid-induced migration ( fig. 4 a, d). Nei-
ther antagonist had any effect on basal HSV SMC migra-
tion when used in the absence of agonist (data not shown). 
 Previous publications have reported effective and se-
lective coupling of GPR35 to Gα 13  [21] , and it is estab-
lished that Gα 13 can promote Rho A activation and sig-
naling via the Rho kinases (ROCK) 1/2 and their effectors 
 [37] . Therefore, to assess the involvement of this signal-
ing pathway in GPR35-promoted HSV SMC migration, 
pamoic acid was coincubated with either of 2 mechanisti-
cally distinct Rho A pathway inhibitors, Y-27632 (10 μ M ) 
 [32] and Y16 (10 μ M )  [33] ( fig. 4 e, f). Both these inhibitors 
prevented pamoic-acid-induced migration (p < 0.001), 
suggesting that GPR35 activation mediates these cell-mi-
gratory effects via the Rho A-ROCK 1/2 signaling axis. 
Next, HSV SMCs were exposed to GPR35 ligands and cell 
proliferation was quantified. Across a range of concentra-
tions, neither zaprinast nor pamoic acid produced a pro-
liferative response in unstimulated, quiesced HSV SMCs 
( fig. 5 a, b). Moreover, neither zaprinast nor pamoic acid 
altered proliferation when HSV SMC proliferation was 
stimulated by the exposure of quiesced HSV SMCs to FCS 
( fig. 5 c, d). This was also the case for the hGPR35 antago-
nists CID-2745687 and ML-145 ( fig. 5 e), indicating that 
the effect of serum on HSV SMC proliferation does not 
reflect the presence of GPR35 agonists within serum.
 Effects of GPR35 Stimulation on HSV EC Migration 
and Proliferation 
 Impaired EC regeneration and function is implicated 
in the incidence of vein graft occlusion, and so the effects 
of GPR35 ligands on HSV EC movement and prolifera-
tion were assessed next. Exposure of HSV ECs to pamoic 
acid did not induce any alterations in morphology or 
 cytoskeletal architecture ( fig. 6 a). Furthermore, using a 
scratch-wound healing assay, no effect on HSV EC mi-
gration was observed whereas the addition of 5% serum 
produced a marked increase in cell migration ( fig. 6 b). 
Next, proliferation was quantified. In contrast to what 
was observed in HSV SMCs, the exposure of quiesced ECs 
to increasing concentrations of zaprinast or pamoic acid 
induced concentration-dependent increases in prolifera-
tion [control 0.67 ± 0.05 arbitrary units (A.U.); 300 n M 
zaprinast 1.55 ± 0.12 A.U.; 300 n M pamoic acid 1.23 ± 0.15 
A.U.], comparable in extent to that achieved with FCS 
(1.29 ± 0.06 A.U.;  fig. 6 c, d). This effect of pamoic acid 
was replicated in an independent assay by assessing BrdU 
incorporation in HSV ECs under identical conditions 
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( fig. 6 e–g), although the extent of the effect of pamoic acid 
in this assay was less than that produced by the addition 
of serum ( fig. 6 e–g). The proliferation induced by con-
centrations of pamoic acid up to 500 n M was completely 
abolished (p < 0.001) in the presence of either CID-
2745687 or ML-145 ( fig. 6 f, g). These data suggest that 
GPR35 activation can mediate HSV EC proliferation and 
that the role of this receptor in migration and prolifera-
tion may be cell type-dependent.
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 Fig. 4. GPR35 mediates HSV SMC migration via the Rho A-ROCK 
signaling axis.  a Representative images of migration in confluent, 
quiescent HSV SMCs in a scratch-wound healing assay,  following 
exposure to 100 n M pamoic acid (PAM) ± 100 n M of the GPR35 
antagonists CID-2745687 (CID) or ML-145. Scale bar = 50 μm. 
HSV SMC migration following exposure to the agonists zaprinast 
(ZAP; n = 4;  b ),  PAM (n = 8;  c ) or  PAM ± the GPR35 antagonists 
CID or ML-145 (n = 5;  d ) was quantified at 0 and 36 h (n = 4–
8; 90 individual measurements/condition/experiment). Scratch 
width was measured via ImageJ and expressed as percent migra-
tion between 0 and 36 h.  e ,  f Migration of confluent, quiescent 
HSV SMCs in the presence of the hGPR35 agonist PAM ± the Rho 
A pathway inhibitors Y-27632 ( e ) or Y-16 ( f ), measured by scratch-
wound healing assay (n = 5; 90 individual scratch measurements/
condition/experiment). Data are shown as means ± SEM.  * * *  p < 
0.001 versus serum control, analyzed via 1-way ANOVA with 
Dunnett’s test for multiple comparisons. 
D
ow
nl
oa
de
d 
by
: 
G
la
sg
ow
 U
ni
v.
Li
b.
   
   
   
   
   
   
   
   
   
   
   
   
  
13
0.
20
9.
11
5.
10
6 
- 4
/1
9/
20
17
 1
0:
24
:5
9 
AM
 GPR35 Modulates Vascular Remodeling  J Vasc Res 2015;52:383–395 
DOI: 10.1159/000444754
391
 Discussion 
 This study is the first to investigate the role GPR35 
may play in primary human VSMC and EC proliferation 
and migration. Recent literature has begun to highlight a 
potential role for GPR35 in a number of disease patholo-
gies including hypertension and heart failure  [28, 29] , 
asthma  [38] , pain  [18, 39] , inflammatory bowel disease 
 [40] and both ulcerative colitis and primary sclerosing 
cholangitis  [41] . To date, GPR35 has been a challenging 
receptor to investigate because of uncertainty about the 
endogenous ligand(s) that activate it  [8, 22] and because 
the majority of synthetic GPR35 agonist ligands display 
either marked species ortholog selectivity or are known 
to have molecular targets in addition to GPR35  [22] . For 
example, the tryptophan metabolite KNU was the first 
reported endogenous GPR35 ligand  [7] , and although 
subsequently confirmed at rat GPR35 with  micromolar 
potency, the activation of hGPR35 was almost undetect-
able in response to this ligand  [21, 42] . Considering that 
circulating plasma concentrations are reported in nano-
molar ranges, although these may increase substantially 
in various inflammatory conditions  [36] , KNU is an un-
likely endogenous ligand at hGPR35  [8] . More recently, 
the chemokine CXCL17 was reported to be an endoge-
nous ligand at GPR35  [43] . Transfection of GPR35 into a 
GPR35-negative cell line led to the induction of CXCL17-
mediated calcium flux following exposure of the cells to 
CXCL17, and induced chemotaxis in THP-1 monocyte 
cells expressing GPR35  [43] . This is an interesting finding 
which requires further study to be consolidated. In the 
search for tool compounds able to interrogate the role of 
GPR35, a large number of ligands with an agonist func-
tion but modest potency have been reported  [12, 22] ; the 
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 Fig. 5. Modulation of GPR35 activation does not stimulate HSV 
SMC proliferation. The proliferation of quiescent HSV SMCs in 
the presence of increasing concentrations of  zaprinast (ZAP; n = 
3;  a ) or pamoic acid (PAM; n = 3;  b ) was measured by MTS assay 
at 48 h and expressed as A.U. The ability of ZAP (n = 4;  c ) or PAM 
(n = 4;  d ) to block HSV SMC proliferation stimulated by exposure 
to 5% FCS was quantified using an MTS assay.  e Assessment of the 
effects of the GPR35 antagonists CID-2745687 (CID; n = 3) or ML-
145 (n = 3) on the serum-induced proliferation of HSV SMCs was 
measured via MTS assay at 48 h. Data are shown as means ± SEM. 
 * * *  p < 0.001 versus serum control, analyzed via 1-way ANOVA, 
with Dunnett’s test for multiple comparisons. 
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first to be identified and the most widely utilized is zapri-
nast  [44] . Although zaprinast has the advantage of dis-
playing agonism at rodent orthologs of GPR35 as well as 
at the human receptor with moderate potency and re-
mains the customary ligand of reference in chemical 
screens targeting novel GPR35 ligands, it is limited in its 
use by its known potency as an inhibitor of cGMP phos-
phodiesterase subtypes. Many other recently described 
GPR35 active ligands also have other targets. Indeed, am-
lexanox  [26] has recently been described as an inhibitor 
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 Fig. 6. GPR35 agonists stimulate HSV EC proliferation.  a Repre-
sentative images of the HSV EC cytoskeleton, stained for F-actin 
following stimulation with 100 n M pamoic acid (PAM) for 45 min 
(n = 3). Scale bar = 50 μm.  b Migration of quiescent HSV ECs is 
unaffected in the presence of increasing concentrations of PAM 
(50, 100 and 500 n M; n = 2; 90 individual scratch measurements/
condition/experiment), measured by scratch-wound healing as-
say. Increasing concentrations of zaprinast (ZAP; n = 3;  c ) or PAM 
(n = 3;  d ) induced proliferation in quiescent HSV EC, as measured 
by MTS or BrdU assay ( e ) following 24 h of ligand exposure. HSV 
EC proliferation in response to GPR35 agonists was blocked via 
coincubation with increasing concentrations (50–500 n M ) of the 
GPR35 antagonists  CID-2745687 (CID;  f ) or ML-145 ( g ), mea-
sured via BrdU assay 24 h after stimulation (n = 2 per agonist/ 
antagonist pair). Data are shown as means ± SEM.  *   p < 0.05, 
 * *  p < 0.01,  * * *  p < 0.001 versus serum control, analyzed via 1-way 
ANOVA with Dunnett’s test for multiple comparisons. 
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of both IKK-ε and TBK1  [45] and is used to target these 
kinases in in vivo studies, despite displaying a markedly 
lower affinity at these kinases than at GPR35  [26, 46] . As 
such, together with zaprinast as a reference ligand, we 
employed pamoic acid as a GPR35 agonist in these stud-
ies. Pamoic acid has a high potency at hGPR35 but very 
modest effects at the rodent orthologs and can therefore 
only be used usefully in studies employing human rather 
than rodent cells and tissues. Perhaps even more impor-
tantly from a pharmacological perspective, there are a 
very limited number of useful antagonists of GPR35. 
Moreover, the 2 key antagonists ML-145 and CID-
2745687 are also entirely specific for the human receptor, 
displaying no useful affinity at either rat or mouse GPR35 
 [14] . Furthermore, it has been previously demonstrated 
that ML-145 displays >1,000-fold selectivity for GPR35 
compared to the most closely related GPCR, GPR55  [24] , 
and since both ML-145 and CID-2745687 were utilized in 
the nanomolar range, it is unlikely that they showed pro-
miscuous activity at other closely related receptors to 
GPR35, such as GPR55 and GPR23. As such, whilst stud-
ies on human cells and tissues are obviously most relevant 
for translation in a therapeutic context, our study was re-
stricted to human tissue-derived cells. Despite this, the 
pharmacological characteristics of these antagonists 
mean that they provide a currently unique opportunity 
to probe the functional importance of GPR35 in disease-
relevant, human cell models. 
 Using these combinations of agonists and antagonists, 
we demonstrate a potentially important role for GPR35 
in the migration of primary HSV SMCs. These cells ex-
press readily detectable levels of GPR35 mRNA that are 
comparable to those found in the spleen and small intes-
tine. The data demonstrate that coincubating a wounded 
monolayer of HSV SMCs with one of the hGPR35-specif-
ic antagonists, CID-2745687 and ML-145, abolished in-
creased migration induced by either of the GPR35 ago-
nists, zaprinast or pamoic acid, thus supporting a specific 
role for GPR35. Investigation of the cellular morphology 
and cytoskeletal rearrangement in HSV SMCs revealed 
significant architectural reorganization of the actin cyto-
skeleton and, similarly, these changes were also prevented 
by the coaddition of the GPR35 antagonists. We hypoth-
esized that the activation of ROCK 1/2 and subsequent 
myosin light-chain phosphorylation would be directly 
linked to the reorganization of the actin cytoskeleton, 
leading to vascular cell contraction and migration  [30, 
47] . To examine this more closely, the effect of the pres-
ence of 2 mechanistically distinct Rho A pathway inhibi-
tors, Y-27632 and Y-16, on the GPR35 agonist-induced 
migration of HSV SMCs was assessed, and both were able 
to block the effects of GPR35 agonism on migration. This 
is entirely consistent with previous observations of the 
selective activation of Gα 13 by GPR35 agonism  [13] , a 
mode of coupling that we have suggested is likely integral 
to the functional roles of GPR35  [8] . Other study groups 
have reported similar effects of Rho kinase 1/2 inhibitors 
in VSMC migration induced by PDGF and lysophospha-
tidic acid in a collagen matrix migration model  [48] . De-
spite ongoing efforts to target Rho A and downstream 
mediators in disease settings, blocking this pathway 
across a broad spectrum of cell types may not be attractive 
therapeutically due to unwanted, off-target side effects 
 [49, 50] . It is proposed, therefore, that compounds which 
mimic this effect, such as GPR35 antagonists, may have 
distinct therapeutic advantages with respect to cell and 
tissue specificity.  
 By further exploring the role of GPR35 in prolifera-
tion, we showed that, at least in HSV SMCs, neither 
GPR35 activation nor inhibition produced any effects on 
cell proliferation. Importantly, this suggests that the find-
ing of increased migration is not confounded by increased 
cell numbers through cell division. Conversely, HSV ECs 
demonstrated significantly enhanced proliferation in the 
presence of increasing concentrations of either zaprinast 
or pamoic acid without effects on migration. Although 
this might be unexpected, it is well established that  GPCRs 
often exhibit diverse effects amongst different cell popu-
lations  [51, 52] . Ruling out potential issues regarding re-
ceptor specificity, it was further demonstrated that the 
proliferation induced by pamoic acid was blocked by the 
presence of the antagonists CID-2745687 and ML-145. 
Taken together with the knowledge that ML-145 has been 
shown to display >1,000-fold selectivity for GPR35 over 
its most closely related receptor GPR55, the specificity of 
the antagonists is likely not an issue here, and, therefore, 
it can be concluded that GPR35 activation plays a role in 
mediating proliferation in HSV ECs. 
 Importantly, this is the first study to report significant 
expression levels of GPR35 in vascular cells and a func-
tional role for hGPR35 in the setting of vascular remodel-
ing. Future investigations that address the mechanism of 
the effects of GPR35 on vascular EC proliferation will be 
integral in our understanding of its true function in the 
vasculature. However, our findings strongly suggest that 
antagonists of GPR35 may be of beneficial therapeutic ef-
fect with respect to attenuating vascular occlusion in the 
setting of vein graft failure.
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